Is PBM Stock Undervalued?

A comprehensive valuation analysis of Psyence Biomedical Ltd (PBM) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated April 19, 2026•8 min read•View Full Analysis

Valuation Verdict

↑

Potentially Undervalued

202205467.6% upside potential

Based on our analysis, Psyence Biomedical Ltd appears to be potentially undervalued at the current price of $7.60. Our fair value estimate of $15367623.14 suggests upside potential of approximately 202205467.6%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing PBM relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

N/A

P/B Ratio

1.46

Moderate

P/S Ratio

N/A

EV/EBITDA

6.32

Low

Understanding the Metrics

P/E Ratio: Not currently profitable or data unavailable.
P/B Ratio: A P/B of 1.46 means investors pay $1.46 for every $1 of book value.
P/S Ratio: Revenue data not available.
EV/EBITDA: This ratio of 6.32 helps compare PBM to peers while accounting for debt.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Psyence Biomedical Ltd stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$7.60

Fair Value Estimate

$15367623.14

Implied Return+202205467.6%

Our DCF model suggests PBM may be undervalued by approximately 202205467.6%. This implies the market may be pricing in more pessimistic growth expectations than our base case scenario.

Investment Conclusion

Bottom Line

Based on our comprehensive valuation analysis, Psyence Biomedical Ltd (PBM) appears to be undervalued at $7.60. With a fair value estimate of $15367623.14, the stock offers potential upside for long-term investors willing to wait for the market to recognize its intrinsic value.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.